Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Usability Standard Aims To Help Firms Institute Human Factors Programs

This article was originally published in The Silver Sheet

Executive Summary

HUMAN FACTORS ENGINEERING IS GETTING A LEG UP with the upcoming release of an international standard that explains how medical device manufacturers can ensure their products are easy to use. Experts believe that better human factors engineering may lead to fewer device recalls and adverse events. Expected to be finalized this fall, IEC 62366 shows firms how risk management and usability work hand-in-hand, referring often to ISO 14971, the voluntary international standard on risk management. "IEC 62366 is an important accessory to ISO 14971, since management of risk associated with device use requires special techniques and processes that are not provided in ISO 14971," says CDRH Human Factors Engineer Pete Carstensen. Meanwhile, FDA has launched a new human factors workgroup that will look at a variety of postmarket issues, including how usability problems are reported by way of the MedSun adverse event reporting system...

You may also be interested in...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts